Hopf R, Thomas J, Klepzig H, Kaltenbach M
Abteilung für Kardiologie, Klinikum der Johann-Wolfgang-Goethe-Universität.
Z Kardiol. 1987 Aug;76(8):469-78.
Fifteen patients (14 males and 1 female) with hypertrophic cardiomyopathy, ranging from 22 to 67 years of age (mean: 45.5 years) were treated with oral nifedipine and propranolol for 6 to 24 (mean: 18) months. Twelve of the patients had been pretreated with a mean oral dose of 560 mg verapamil for 60 to 93 (mean 78.5) months, showing slight subjective and objective improvement. Treatment with nifedipine and propranolol was terminated in five cases, due to deterioration or side effects after 6 and 12 months, respectively. During combined therapy, two patients reported improvement, whereas in five cases there was no change and eight patients reported deterioration. There was no change in the Sokolow index. The radiologically determined heart volume increased in 10 out of 15 patients and in the total group from 887 +/- 214 to 938 +/- 248 ml/1.73 m2. Echocardiographic measurements showed a significant increase in left atrial diameter from 40.0 +/- 9 to 44.0 +/- 11 mm, whereas ventricular wall thickness remained unchanged. Thus, high-dose verapamil therapy seems superior to nifedipine-propranolol therapy in patients with hypertrophic cardiomyopathy.
15例肥厚型心肌病患者(14例男性,1例女性),年龄在22岁至67岁之间(平均45.5岁),接受口服硝苯地平和普萘洛尔治疗6至24个月(平均18个月)。其中12例患者曾接受平均口服剂量560 mg维拉帕米治疗60至93个月(平均78.5个月),主观和客观症状均有轻微改善。由于分别在6个月和12个月后病情恶化或出现副作用,5例患者终止了硝苯地平和普萘洛尔治疗。联合治疗期间,2例患者症状改善,5例无变化,8例患者症状恶化。索科洛指数无变化。15例患者中有10例经放射学测定心脏容积增加,全组心脏容积从887±214增加至938±248 ml/1.73 m²。超声心动图测量显示左心房直径从40.0±9显著增加至44.0±11 mm,而心室壁厚度保持不变。因此,在肥厚型心肌病患者中,大剂量维拉帕米治疗似乎优于硝苯地平 - 普萘洛尔治疗。